Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16833111 | 0.88 | RAB9A (0.86) | RAB9ANPC1ALDH1A1TDP1HTT | |
| SCHEMBL16855655 | 0.85 | RAB9A (0.58) | RAB9ANPC1ALDH1A1TDP1HTT | |
| SCHEMBL16832464 | 0.78 | NPC1 (0.53) | RAB9ANPC1ALDH1A1KDM4EPKM | |
| SCHEMBL18483483 | 0.74 | RAB9A (0.61) | RAB9ANPC1ALDH1A1TDP1HTT | |
| SCHEMBL16832564 | 0.72 | RAB9A (0.77) | RAB9ANPC1ALDH1A1TDP1HTT | |
| SCHEMBL16855412 | 0.71 | NPC1 (0.48) | RAB9ANPC1ALDH1A1HTTLMNA | |
| SCHEMBL16855409 | 0.71 | ALDH1A1 (0.44) | RAB9ANPC1ALDH1A1TDP1HTT | |
| SCHEMBL16855481 | 0.70 | GAA (0.57) | ALDH1A1HTTLMNAPOLBSMN1; SMN2 | |
| SCHEMBL16855660 | 0.69 | GAA (0.56) | RAB9AALDH1A1HTTLMNAL3MBTL1 | |
| SCHEMBL16855410 | 0.69 | ALDH1A1 (0.50) | RAB9ANPC1ALDH1A1TDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | RAB9A 1843/4885NPC1 58/4885ALDH1A1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.